Analyst Joanna Gajuk from Bank of America Securities reiterated a Buy rating on BrightSpring Health Services, Inc. and increased the price target to $41.00 from $38.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joanna Gajuk’s rating is based on BrightSpring Health Services, Inc.’s promising growth outlook and strategic initiatives. The company anticipates a continuation of its strong performance with double-digit EBITDA growth projected for 2026, driven by market share gains, cost efficiencies, and strategic acquisitions. The Infusion and Specialty Pharmacy segments are expected to be key contributors to this growth.
Moreover, the Specialty Pharmacy division has shown impressive revenue growth, supported by exclusive contracts for new drug launches and generic conversions that enhance profit margins. The company is also expanding its infusion services, aiming for significant EBITDA growth through standardization and scaling efforts. Additionally, BrightSpring’s hospice services are set to grow robustly, and while there are concerns about home health rate updates, the company’s recent acquisitions present unique opportunities for integration and expansion.